Aflibercept for Relapsed Multiple Myeloma

Conditions

• Stage II Multiple Myeloma
• Stage III Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• aflibercept — BIOLOGICAL
  Given IV

Study Details

This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. It may also stop the growth of multiple myeloma by blocking blood flow to the cancer.

Key Dates

Start date

Jan 31, 2007

Status verified

Jan 2021

Primary completion

Oct 31, 2010

Completion

Apr 30, 2011

Study Design

Enrollment

6 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (antiangiogenesis therapy)
  Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall Response Rate (Complete [CR] and Partial Response [PR]) [ Time Frame: At baseline and every 4 weeks during study treatment until treatment discontinuation due to disease progression, unacceptable toxicities and/or patient withdrawal. ]

Locations (6)

Find similar trials in Manhasset, NY